Stocktoria
Connect Biopharma Holdings Ltd CNTB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-19
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $64,000 | $26.0M | $0 |
| Operating income | -$58.1M | -$22.5M | -$69.1M |
| Net income | -$55.5M | -$15.6M | -$62.1M |
| Operating cash flow | -$51.2M | -$23.6M | -$47.7M |
| Free cash flow | -$51.6M | -$24.4M | -$47.8M |
| Total assets | $56.1M | $101.3M | $127.4M |
| Total liabilities | $14.1M | $9.1M | $25.9M |
| Shareholders' equity | $42.0M | $92.2M | $101.5M |
| Ratios | |||
| Operating margin | -90740.6% | -86.2% | — |
| Net margin | -86687.5% | -60.0% | — |
| FCF margin | -80687.5% | -93.6% | — |
| Return on assets | -98.9% | -15.4% | -48.8% |
| Return on equity | -132.2% | -17.0% | -61.2% |
| Current ratio | 3.74 | 11.46 | 4.85 |
| Revenue growth | -99.8% | — | — |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001835268 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.